Sign in
CTIC Stock Price, Chart, Stats & News
CTI BioPharma Corp.
Save
1.20B
Market cap
–
Current P/E
–
Forward P/E
CTIC chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 93.49% |
Operating margin | -147.91% |
Pretax margin | -172.37% |
Net margin | -168.76% |
Effective tax rate | 2.10% |
ROA | -72.30% |
ROE | 1318.48% |
D/E | -2.84x |
Interest coverage ratio | -6.07x |
CTIC valuation
P/E | – |
P/S | 22.23x |
P/B | -59.35x |
P/CF | -12.85x |
P/FCF | -11.29x |
P/OCF | -12.85x |
PEG | -0.11x |
EV multiple | -14.78x |
About
CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery, advancement, and commercialization of innovative, targeted treatments for blood cancers within the United States. Its key product is VONJO (pacritinib), an oral kinase inhibitor currently under investigation, specifically designed to target JAK2, FLT3, IRAK1, and CSF1R for the management of adult patients with myelofibrosis. The company holds licensing and collaboration agreements with Teva Pharmaceutical Industries Ltd., SBIO Pte Ltd., and Baxalta.
Similar securities
Based on sector and market capitalization
Report issue